Efficacy and Safety of Colloids Versus Crystalloids for Fluid Resuscitation in Critically Ill Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00318942|
Recruitment Status : Completed
First Posted : April 27, 2006
Last Update Posted : July 1, 2014
Background: Two recent systematic reviews of the literature and meta-analyses have suggested that colloids administration might be deleterious in critically ill patients.
Objective: To compare the effects on hospital mortality of crystalloids and colloids when given for fluid resuscitation in critically ill patients.
Setting: Adult intensive care units (ICUs) in several European countries.
Study design: A multinational, randomised, controlled trial performed on two parallel groups.
Intervention: Any type of crystalloids (control group) versus any type of colloids (including albumin).
Patients: All patients above the legal age of consent and hospitalised in an intensive care unit, who need fluid resuscitation (according to the physician). Pregnant women, moribund patients, brain dead patients, and patients who have a known allergy to colloids or severe head injury or major burns (> 20% of body surface) or dehydration will not be included.
Primary endpoint: 28-day mortality.
Hypothesis: Assuming a hospital mortality rate of 20% in the crystalloids group, a 0.05 type I error, 3010 patients are needed to show a difference between the 2 groups of 5% with a 90% probability (two-sided test).
|Condition or disease||Intervention/treatment||Phase|
|Critical Illness||Drug: Crystalloids Drug: Colloids||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2857 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||CRISTAL: Colloids Compared to Crystalloids in Fluid Resuscitation of Critically Ill Patients: A Multinational Randomised Controlled Trial|
|Study Start Date :||February 2003|
|Actual Primary Completion Date :||August 2012|
|Actual Study Completion Date :||November 2012|
Active Comparator: 1
Crystalloids, any type of Crystalloids including isotonic or hypertonic saline, Ringer Lactates either modified or not
Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay
Any crystalloids given for correction of hypovolemia during all ICU stay
Colloids, including albumin, gelatines, starch any other synthetic colloids
Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay
Any colloids given for correction of hypovolemia during all ICU stay
- 28-day mortality [ Time Frame: Day 28 ]
- ICU and hospital mortality rates [ Time Frame: Day 90 ]
- Number of days free of mechanical ventilation (MV), vasopressors, renal replacement therapy, and organ system failure [ Time Frame: Day 90 ]
- Difference in the area under the curve (AUC) of mean arterial pressure (MAP) from HO to H24, in weight gain, in PaO2/FiO2 ratio, chest X-ray score [ Time Frame: Day 2 ]
- Frequency of adverse events [ Time Frame: day 90 ]
- Length of stay (LOS) [ Time Frame: Day 90 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00318942
|Study Chair:||Djillali Annane, MD, PhD||Assistance Publique Hôpitaux de Paris - University of Versailles|